Breaking News
Get 50% Off 0
Final days! 🔥 Up to 50% OFF InvestingPro
CLAIM SALE
Close

Fate Therapeutics Inc (FATE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Fate Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.090 -0.060    -5.22%
25/08 - Closed. Currency in USD
After Hours
1.080
-0.010
-0.917%
0:25:03 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,410,875
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.070 - 1.170
Fate Therapeutics 1.090 -0.060 -5.22%

Fate Therapeutics Inc Company Profile

 
Get an in-depth profile of Fate Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

181

Equity Type

ORD

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Contact Information

Address 12278 Scripps Summit Drive
San Diego, 92131
United States
Phone 858 875 1800
Fax -

Top Executives

Name Age Since Title
William H. Rastetter 74 2011 Independent Chairman
John D. Mendlein 65 2007 Independent Vice Chairman of the Board
Bahram Valamehr 48 2018 President, CEO & Director
Mark Krasnow - 2010 Member of Scientific Advisory Board
Bennett M. Shapiro 85 - Member of Scientific Advisory Board
Robert S. Langer 76 - Member of Scientific Advisory Board
Stuart Orkin - 2010 Member of Scientific Advisory Board
Robert S. Epstein 70 2014 Independent Director
Karin Jooss 59 2019 Independent Director
Sui Huang - 2010 Member of Scientific Advisory Board
Sean J. Morrison - 2010 Member of Scientific Advisory Board
Lynn Megeney - 2010 Member of Scientific Advisory Board
Steven L. Goldstein - 2010 Member of Scientific Advisory Board
Shefali Agarwal 52 2019 Independent Director
Alberto Hayek - 2010 Member of Scientific Advisory Board
Michael Stewart Lee 46 2018 Independent Director
Yuan Xu 57 2021 Independent Director
Neely Mozaffarian 57 2024 Independent Director
Matthew C. Abernethy 45 2025 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FATE Comments

Write your thoughts about Fate Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email